United States News Todas as matérias

Fortuna Mining (NYSE:FSM) reported gold mineralization below Lindero's current reserve pit design, including a 350-meter intersection averaging 0.96 grams per tonne.

Mercantile Bank Corporation (NASDAQ:MBWM) declared a quarterly cash dividend of $0.40 per common share, payable December 16, 2026, to eligible shareholders.

Cognizant (NASDAQ:CTSH) announced a five-year agreement with payment technology company Ingenico to modernize its global technology infrastructure, applications and data operations.

Brent crude futures rose 0.47% to $110.07 per barrel on October 20, 2026, as Middle Eastern security risks supported oil prices.

BW LPG (NYSE:BWLP) announced an agreement to sell its 2008-built BW Loyalty vessel, expecting an approximately $52 million disposal gain.

Anteris Technologies Global (NASDAQ:AVR) received full German regulatory clearance to recruit patients for its global PARADIGM trial evaluating the DurAVR heart valve.

Grupo Aeroportuario del Pacífico (NYSE:PAC) reported third-quarter 2026 net income of Ps. 2,914.1 million, an 8.1% increase from a year earlier.

Oracle (NYSE:ORCL) announced a non-binding collaboration with AstraZeneca (NASDAQ:AZN) to explore artificial intelligence and real-world data applications in clinical research.

Oculis (NASDAQ:OCS) will present new Phase 2 ACUITY biomarker analyses of its investigational Privosegtor treatment on October 22, 2026, in Toronto.

Kenvue (NYSE:KVUE) lost its bid to reconsider a federal appeals ruling reviving approximately 500 lawsuits alleging prenatal Tylenol exposure caused autism or ADHD.

Apple (NASDAQ:AAPL) faces potential additional patent damages after Taction Technology requested interest and compensation beyond a September jury verdict exceeding $5.7 billion.

United Therapeutics (NASDAQ:UTHR) received FDA clearance to proceed with a Phase 2 trial of treprostinil SMI for pulmonary hypertension associated with COPD.

Cullinan Therapeutics (NASDAQ:CGEM) and Taiho Oncology reported a 30.2% intracranial response rate for zipalertinib in 43 evaluable lung cancer patients with brain metastases.

Summit Therapeutics (NASDAQ:SMMT) announced the opening of a Phase 2 kidney cancer trial evaluating ivonescimab-based treatments in approximately 100 patients across two countries.

Veradermics (NYSE:MANE) reported positive Phase 3 results for VDPHL01, with both dosing regimens significantly increasing hair counts versus placebo after six months.

Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.

The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.

VinFast (NASDAQ:VFS) reported second-quarter 2026 revenue of $1.20 billion, up 85.5% year over year, supported by higher electric vehicle deliveries.

Peoples Bancorp of North Carolina (NASDAQ:PEBK) reported third-quarter 2026 net earnings of $5.7 million, up approximately 54% from $3.7 million a year earlier.

Alpha Tau Medical (NASDAQ:DRTS) received FDA authorization to expand its REGAIN brain cancer trial from 10 to 20 patients across three U.S. centers.

Eos Energy Enterprises (NASDAQ:EOSE) expects preliminary third-quarter 2026 revenue of US$82–US$83 million, representing 169%–172% growth from the prior year.

TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.

Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.

Blackstone (NYSE:BX) closed its fifth energy transition private equity fund at US$8.7 billion, exceeding its predecessor's US$5.6 billion fundraising total by approximately 55%.

Dynex Capital (NYSE:DX) reported a negative 11.5% economic return for Q3 2026, as book value declined to $10.91 per share.